CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Jazz Pharmaceuticals plc - JAZZ CFD

    114.17
    0.14%
    0.25
    Low: 113.72
    High: 115.29
    Market Trading Hours* (UTC) Opens on Thursday at 14:30

    Mon - Fri: 14:30 - 21:00

    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.25
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026207 %
    Charges from full value of position ($-4.98)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026207%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003985 %
    Charges from full value of position ($0.76)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003985%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Jazz Pharmaceuticals PLC ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 114.35
    Open* 114.86
    1-Year Change* -25.31%
    Day's Range* 113.72 - 115.29
    52 wk Range 115.97-160.96
    Average Volume (10 days) 990.33K
    Average Volume (3 months) 13.75M
    Market Cap 7.45B
    P/E Ratio 196.06
    Shares Outstanding 62.96M
    Revenue 3.79B
    EPS 0.60
    Dividend (Yield %) N/A
    Beta 0.68
    Next Earnings Date Feb 26, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Nov 29, 2023 114.19 0.82 0.72% 113.37 115.58 113.37
    Nov 28, 2023 114.35 -2.30 -1.97% 116.65 116.72 111.05
    Nov 27, 2023 117.04 -1.57 -1.32% 118.61 119.75 116.89
    Nov 24, 2023 121.15 0.83 0.69% 120.32 122.51 120.32
    Nov 22, 2023 121.21 3.44 2.92% 117.77 122.18 117.76
    Nov 21, 2023 118.19 -1.28 -1.07% 119.47 120.29 117.98
    Nov 20, 2023 120.21 0.73 0.61% 119.48 121.17 119.32
    Nov 17, 2023 120.13 -0.46 -0.38% 120.59 121.95 119.87
    Nov 16, 2023 121.40 -3.14 -2.52% 124.54 124.55 118.50
    Nov 15, 2023 124.99 1.92 1.56% 123.07 125.93 123.00
    Nov 14, 2023 124.29 1.48 1.21% 122.81 125.28 121.81
    Nov 13, 2023 121.86 3.40 2.87% 118.46 122.56 117.10
    Nov 10, 2023 120.09 3.81 3.28% 116.28 120.91 115.68
    Nov 9, 2023 116.48 -10.12 -7.99% 126.60 127.69 116.03
    Nov 8, 2023 127.92 -5.77 -4.32% 133.69 133.69 127.25
    Nov 7, 2023 133.48 1.53 1.16% 131.95 134.42 131.57
    Nov 6, 2023 132.27 1.71 1.31% 130.56 133.52 130.55
    Nov 3, 2023 131.97 3.46 2.69% 128.51 132.25 128.51
    Nov 2, 2023 128.41 1.33 1.05% 127.08 128.86 125.98
    Nov 1, 2023 126.86 -0.08 -0.06% 126.94 128.71 126.12

    Jazz Pharmaceuticals plc Events

    Time (UTC) Country Event
    Monday, February 26, 2024

    Time (UTC)

    21:05

    Country

    IE

    Event

    Q4 2023 Jazz Pharmaceuticals PLC Earnings Release
    Q4 2023 Jazz Pharmaceuticals PLC Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 3659.37 3094.24 2363.57 2161.76 1890.92
    Revenue 3659.37 3094.24 2363.57 2161.76 1890.92
    Cost of Revenue, Total 540.517 440.76 148.917 127.93 121.544
    Gross Profit 3118.86 2653.48 2214.65 2033.83 1769.38
    Total Operating Expense 3724.9 2923.96 1990.59 1629.39 1277.51
    Selling/General/Admin. Expenses, Total 1376.17 1222.68 854.233 736.942 683.53
    Research & Development 1034.6 505.748 586.625 409.701 226.616
    Depreciation / Amortization 599.169 525.769 259.58 354.814 201.498
    Unusual Expense (Income) 174.448 229 141.239 0 44.321
    Operating Income -65.528 170.278 372.973 532.374 613.413
    Interest Income (Expense), Net Non-Operating -307.256 -283.116 -97.878 -78.072 -86.153
    Net Income Before Taxes -372.784 -112.838 275.095 454.302 527.26
    Net Income After Taxes -214.139 -328.954 241.578 527.456 447.091
    Minority Interest
    Net Income Before Extra. Items -224.06 -329.668 238.616 523.367 447.091
    Net Income -224.06 -329.668 238.616 523.367 447.098
    Income Available to Common Excl. Extra. Items -224.06 -329.668 238.616 523.367 447.091
    Income Available to Common Incl. Extra. Items -224.06 -329.668 238.616 523.367 447.098
    Dilution Adjustment 0
    Diluted Net Income -224.06 -329.668 238.616 523.367 447.098
    Diluted Weighted Average Shares 62.539 59.694 56.517 57.55 61.221
    Diluted EPS Excluding Extraordinary Items -3.58272 -5.52263 4.22202 9.09413 7.30289
    Diluted Normalized EPS -1.7696 -3.02908 6.4166 9.09413 7.91677
    Total Extraordinary Items 0 0.0075
    Equity In Affiliates -9.921 -0.714 -2.962 -4.089
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 957.317 892.812 972.123 940.652 932.878
    Revenue 957.317 892.812 972.123 940.652 932.878
    Cost of Revenue, Total 97.537 128.644 167.364 133.661 124.208
    Gross Profit 859.78 764.168 804.759 806.991 808.67
    Total Operating Expense 799.681 766.757 1235.51 915.889 847.332
    Selling/General/Admin. Expenses, Total 340.844 297.917 383.203 317.678 325.673
    Research & Development 209.238 190.41 547.555 148.87 208.195
    Depreciation / Amortization 152.062 149.786 137.387 141.232 148.456
    Unusual Expense (Income) 0 174.448 40.8
    Operating Income 157.636 126.055 -263.386 24.763 85.546
    Interest Income (Expense), Net Non-Operating -75.852 -70.954 -76.607 -84.893 -64.532
    Net Income Before Taxes 81.784 55.101 -339.993 -60.13 21.014
    Net Income After Taxes 106.107 70.425 -239.951 -17.103 37.126
    Equity In Affiliates -1.669 -1.005 -0.773 -2.545 -2.461
    Net Income Before Extra. Items 104.438 69.42 -240.724 -19.648 34.665
    Net Income 104.438 69.42 -240.724 -19.648 34.665
    Income Available to Common Excl. Extra. Items 104.438 69.42 -240.724 -19.648 34.665
    Income Available to Common Incl. Extra. Items 104.438 69.42 -240.724 -19.648 34.665
    Diluted Net Income 104.438 69.42 -240.724 -19.648 34.665
    Diluted Weighted Average Shares 73.54 73.771 63.061 62.785 63.431
    Diluted EPS Excluding Extraordinary Items 1.42015 0.94102 -3.81732 -0.31294 0.5465
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS 1.42015 0.94102 -3.81732 1.49308 0.96459
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 2606.14 2611.33 2839.57 1630.27 1234.01
    Cash and Short Term Investments 881.482 591.448 2132.77 1077.34 824.622
    Cash & Equivalents 517.464
    Short Term Investments 30 80.701 1615.65 744.172 609.016
    Total Receivables, Net 742.628 563.36 396.49 355.987 263.838
    Accounts Receivable - Trade, Net 651.493 563.36 396.49 355.987 263.838
    Total Inventory 714.061 1072.72 95.396 78.608 52.956
    Prepaid Expenses 91.912 131.413 62.422 39.434 25.017
    Other Current Assets, Total 176.057 252.392 152.491 78.895 67.572
    Total Assets 10835.3 12298.6 6535.9 5538.9 5203.49
    Property/Plant/Equipment, Total - Net 301.376 343.423 257.104 270.891 200.358
    Property/Plant/Equipment, Total - Gross 409.023 428.794 324.692 326.148 249.966
    Accumulated Depreciation, Total -107.647 -85.371 -67.588 -55.257 -49.608
    Goodwill, Net 1692.66 1827.61 958.303 920.018 927.63
    Intangibles, Net 5794.44 7152.33 2195.05 2440.98 2731.33
    Other Long Term Assets, Total 440.64 363.945 285.875 276.743 110.164
    Total Current Liabilities 933.193 809.303 653.745 364.49 345.487
    Accounts Payable 90.758 100.298 26.945 47.545 40.602
    Accrued Expenses 802.874 647.479 349.107 266.836 263.427
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases 31.381 31.406 246.322 33.387 33.387
    Other Current Liabilities, Total 8.18 30.12 31.371 16.722 8.071
    Total Liabilities 7749.52 8333.45 2876.16 2427.92 2446.07
    Total Long Term Debt 5698.55 6025.21 1848.52 1573.87 1563.03
    Long Term Debt 5693.34 6018.94 1848.52 1573.87 1563.03
    Deferred Income Tax 944.337 1300.54 130.397 224.095 309.097
    Other Liabilities, Total 173.44 198.392 243.498 265.461 228.46
    Total Equity 3085.73 3965.19 3659.75 3110.98 2757.42
    Common Stock 0.061 0.061 0.061 0.061 0.061
    Additional Paid-In Capital 3477.12 3534.79 2633.67 2266.03 2113.63
    Retained Earnings (Accumulated Deficit) 734.058 830.698 1160.37 1068.29 841.522
    Other Equity, Total -1125.51 -400.36 -134.352 -223.393 -197.791
    Total Liabilities & Shareholders’ Equity 10835.3 12298.6 6535.9 5538.9 5203.49
    Total Common Shares Outstanding 63.214 61.633 56.171 56.14 57.504
    Cash 334.018 510.747 517.117 333.172 215.606
    Capital Lease Obligations 5.21 6.269
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 3245.75 3009.85 2784.65 2606.14 2571.5
    Cash and Short Term Investments 1585.69 1362.3 1167.91 881.482 899.358
    Cash 366.1 331.37 424.139 334.018 296.686
    Cash & Equivalents 409.59 650.934 563.772 517.464 542.672
    Short Term Investments 810 380 180 30 60
    Total Receivables, Net 729.236 683.194 681.154 651.493 601.179
    Accounts Receivable - Trade, Net 627.841 610.389 623.938 651.493 601.179
    Total Inventory 611.827 657.214 674.778 714.061 728.074
    Prepaid Expenses 109.99 107.49 72.779 91.912 92.877
    Other Current Assets, Total 209.009 199.653 188.028 267.192 250.016
    Total Assets 11204.1 11260.5 11047.1 10835.3 10384.7
    Property/Plant/Equipment, Total - Net 287.514 298.304 303.09 301.376 290.067
    Property/Plant/Equipment, Total - Gross 412.333 418.749 419.23 409.023 388.038
    Accumulated Depreciation, Total -124.819 -120.445 -116.14 -107.647 -97.971
    Goodwill, Net 1705.32 1742.68 1723.44 1692.66 1592.64
    Intangibles, Net 5417.86 5705.78 5764.21 5794.44 5570.39
    Other Long Term Assets, Total 547.619 503.929 471.732 440.64 360.067
    Total Current Liabilities 1573.33 945.265 908.902 933.193 812.954
    Accounts Payable 109.85 98.428 125.454 90.758 102.249
    Accrued Expenses 753.978 746.65 711.779 803.255 630.648
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases 604.507 31 31 31 31
    Other Current Liabilities, Total 104.994 69.187 40.669 8.18 49.057
    Total Liabilities 7714.69 7734.87 7712.08 7749.52 7639.47
    Total Long Term Debt 5110.76 5686.65 5689.66 5693.34 5695.81
    Long Term Debt 5110.76 5686.65 5689.66 5693.34 5695.81
    Deferred Income Tax 841.234 910.724 932.247 944.337 933.67
    Other Liabilities, Total 189.372 192.23 181.273 178.65 197.035
    Total Equity 3489.37 3525.68 3335.04 3085.73 2745.19
    Common Stock 0.061 0.061 0.061 0.061 0.061
    Additional Paid-In Capital 3639.94 3580.11 3511.73 3477.12 3388
    Retained Earnings (Accumulated Deficit) 884.771 812.322 803.478 734.058 974.782
    Other Equity, Total -1035.4 -866.823 -980.23 -1125.51 -1617.65
    Total Liabilities & Shareholders’ Equity 11204.1 11260.5 11047.1 10835.3 10384.7
    Total Common Shares Outstanding 62.945 63.398 63.987 63.214 62.89
    Capital Lease Obligations
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -224.06 -329.668 238.616 523.367 447.098
    Cash From Operating Activities 1271.98 778.507 899.648 776.401 798.904
    Cash From Operating Activities 30.302 26.714 18.673 15.342 15.233
    Amortization 599.169 525.769 259.58 354.814 201.498
    Deferred Taxes -292.251 69.198 -136.937 -236.61 -88.815
    Non-Cash Items 875.52 311.361 605.153 269.572 200.604
    Cash Taxes Paid 94.681 271.217 226.823 183.61 164.217
    Cash Interest Paid 270.671 138.271 42.47 43.002 42.706
    Changes in Working Capital 283.297 175.133 -85.437 -150.084 23.286
    Cash From Investing Activities -446.23 -5212.14 -1007.67 -155.3 -394.487
    Capital Expenditures -498.194 -45.532 -379.254 -182.335 -131.47
    Other Investing Cash Flow Items, Total 51.964 -5166.61 -628.416 27.035 -263.017
    Cash From Financing Activities -529.491 3970.52 528.073 -293.745 -479.13
    Financing Cash Flow Items -45.443 -35.602 -16.877 -16.739 -23.078
    Issuance (Retirement) of Stock, Net 97.966 135.261 -46.856 -243.619 -430.335
    Issuance (Retirement) of Debt, Net -582.014 3870.86 591.806 -33.387 -25.717
    Foreign Exchange Effects -6.222 -3.207 0.374 0.366 -1.7
    Net Change in Cash 290.034 -466.321 420.425 327.722 -76.413
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line 69.42 -224.06 16.664 36.312 1.647
    Cash From Operating Activities 320.708 1271.98 930.006 512.015 208.979
    Cash From Operating Activities 7.574 30.302 22.958 15.364 7.617
    Amortization 149.786 599.169 461.782 320.55 172.094
    Deferred Taxes -66.061 -292.251 -146.874 -82.315 -45.339
    Non-Cash Items 81.207 875.52 421.208 208.514 49.707
    Changes in Working Capital 78.782 283.297 154.268 13.59 23.253
    Cash From Investing Activities -4.822 -446.23 -121.852 -126.454 -37.292
    Capital Expenditures -4.822 -498.194 -113.816 -118.718 -37.292
    Other Investing Cash Flow Items, Total 51.964 -8.036 -7.736 0
    Cash From Financing Activities -29.788 -529.491 -549.087 -260.034 -270.811
    Financing Cash Flow Items -43.266 -45.443 -42.632 -40.065 -33.776
    Issuance (Retirement) of Stock, Net 21.228 97.966 67.809 46.549 21.729
    Issuance (Retirement) of Debt, Net -7.75 -582.014 -574.264 -266.518 -258.764
    Foreign Exchange Effects 0.331 -6.222 -11.157 -5.71 -1.489
    Net Change in Cash 286.429 290.034 247.91 119.817 -100.613
    Cash Taxes Paid 94.681
    Cash Interest Paid 270.671
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 10.2629 6479474 163640 2023-08-31 LOW
    BlackRock Institutional Trust Company, N.A. Investment Advisor 8.7097 5498852 130439 2023-06-30 LOW
    State Street Global Advisors (US) Investment Advisor/Hedge Fund 3.7577 2372395 42703 2023-06-30 LOW
    LSV Asset Management Investment Advisor 3.6692 2316547 -1856 2023-06-30 LOW
    Wellington Management Company, LLP Investment Advisor/Hedge Fund 2.9581 1867582 11642 2023-06-30 LOW
    JP Morgan Asset Management Investment Advisor 2.554 1612482 -297493 2023-06-30 LOW
    Samlyn Capital, LLC Hedge Fund 2.1323 1346230 557605 2023-06-30 HIGH
    Renaissance Technologies LLC Hedge Fund 2.0434 1290109 35500 2023-06-30 HIGH
    Deep Track Capital LP Hedge Fund 1.9799 1250000 50000 2023-06-30 MED
    Polaris Capital Management, LLC Investment Advisor 1.9646 1240360 -56300 2023-09-30 LOW
    Columbia Threadneedle Investments (US) Investment Advisor/Hedge Fund 1.9559 1234872 66367 2023-06-30 LOW
    Mulligan (Seamus C) Individual Investor 1.8529 1169814 3075 2023-08-11 LOW
    Swedbank Robur Fonder AB Investment Advisor/Hedge Fund 1.7477 1103381 14992 2023-09-30 LOW
    Franklin Advisers, Inc. Investment Advisor/Hedge Fund 1.7308 1092730 -192632 2023-06-30 LOW
    Fidelity Management & Research Company LLC Investment Advisor 1.6451 1038652 129999 2023-06-30 LOW
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.5809 998067 44286 2023-06-30 LOW
    Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund 1.3019 821923 -18080 2023-06-30 LOW
    Avidity Partners Management LP Hedge Fund 1.1131 702778 24878 2023-06-30 HIGH
    Pacer Advisors, Inc. Investment Advisor 1.0839 684289 206243 2023-06-30 MED
    The Baupost Group, L.L.C. Investment Advisor/Hedge Fund 1.0671 673696 195000 2023-06-30

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Jazz Pharma Company profile

    About Jazz Pharmaceuticals PLC

    Jazz Pharmaceuticals Public Limited Company is a biopharmaceutical company. The Company is focused on developing and commercializing products that address unmet medical needs. The Company has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. The Company's lead marketed products include Xyrem (sodium oxybate oral solution) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze for the treatment of acute lymphoblastic leukemia (ALL), and Defitelio (defibrotide) for the treatment of severe hepatic veno-occlusive disease (VOD). The Company also commercializes Prialt, an intrathecally administered infusion of ziconotide, approved by the FDA for the management of severe chronic pain in patients for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies or intrathecal morphine.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, Jazz Pharmaceuticals PLC revenues increased 31% to $3.09B. Net loss totaled $329.7M vs. income of $238.6M. Revenues reflect Sunosi segment increase from $28.3M to $2.34B, Zepzelca segment increase from $90.4M to $246.8M, United States segment increase of 32% to $2.82B, Europe segment increase of 31% to $230.2M. Net loss reflects Selling.

    Equity composition

    Common Stock $.0001 Par, 4/11, 150M auth., 40,741,809 issd. Insiders & stakeholders own 2.30%. IPO 6/1/07, 6M shares @ $18 per share by Morgan Stanley & Co. Incorporated, Lehman Brothers Inc. 5/07 Reverse stock split 1 for 11.06701. PO: 7/08, 3.8M shares.

    Industry: Pharmaceuticals (NEC)

    Fifth Fl
    Waterloo Exchange
    DUBLIN
    DUBLIN 4
    IE

    Income Statement

    • Annual
    • Quarterly

    News

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023
    GBP

    UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?

    UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.

    10:48, 21 November 2023

    Gold Rises as Traders price-in Fed Rate Cuts

    Gold prices have declined despite a drop in Treasury yields and a weaker US Dollar. We look at the key drivers and technical levels for the gold price.

    13:17, 20 November 2023

    People also watch

    Gold

    2,045.73 Price
    +0.210% 1D Chg, %
    Long position overnight fee -0.0196%
    Short position overnight fee 0.0114%
    Overnight fee time 22:00 (UTC)
    Spread 0.30

    US100

    16,019.90 Price
    +0.050% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0040%
    Overnight fee time 22:00 (UTC)
    Spread 1.8

    XRP/USD

    0.61 Price
    -0.670% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 22:00 (UTC)
    Spread 0.01168

    BTC/USD

    37,919.90 Price
    -0.270% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 22:00 (UTC)
    Spread 106.00

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading